ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 1588
“Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA”
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1614
“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1753
“Recurrent Venous Thromboembolic Events in Granulomatosis with Polyangiitis Patients”
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1275
101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis
9:00AM-11:00AM
Abstract Number: 1355
14-3-3η:  Useful for More Than the Diagnosis of Rheumatoid Arthritis?
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1643
15 Year Comparative Analysis of Cardiovascular Events in Female Subjects with Lupus Versus Controls
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1699
A 10-Year National Trend in Acute Coronary Syndrome Among Hospitalized Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II
9:00AM-11:00AM
Abstract Number: 1142
A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality
Metabolic and Crystal Arthropathies Poster I
9:00AM-11:00AM
Abstract Number: 1134
A Case Series of Gout and Downs Syndrome – a New Paradigm for Detecting Disease Associations Using Big Data
Metabolic and Crystal Arthropathies Poster I
9:00AM-11:00AM
Abstract Number: 1055
A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting
Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 959
A Disintegrin and Metalloprotease -17 Is Overexpressed on Rheumatoid Arthritis Osteoblasts and Is Regulated with TNF-α Stimulation
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?
9:00AM-11:00AM
Abstract Number: 957
A Disintegrin and Metalloprotease 15 Is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and Mediates Angiogenesis
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?
9:00AM-11:00AM
Abstract Number: 1703
A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II
9:00AM-11:00AM
Abstract Number: 1328
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Rheumatoid Arthritis – Animal Models Poster II
9:00AM-11:00AM
Abstract Number: 1163
A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
  • 1
  • 2
  • 3
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences